therapeutic candidate News
-
Showcase
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule. The Round 2 MMF grants, part of the Government’s Modern Manufacturing Strategy, are for small-medium sized businesses to transform manufacturing and to support job growth and develop a more skilled ...
-
Results from Symic Bio Liver Fibrosis Program Presented at the International Liver Congress 2018
SAN FRANCISCO, April 16, 2018 – Symic Bio, a biopharmaceutical company developing novel biotherapeutics targeting the extracellular matrix, presented results from a lead candidate therapy for liver fibrosis at the International Liver Congress 2018, the annual meeting of the European Association for the Study of the Liver, held April 11-15, 2018, in Paris. Results demonstrated that treatment ...
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st. Event: Piper Sandler 34th Annual ...
By Lumos Pharma
-
Airfinity launches new platform IDA 360 to track all infectious disease vaccine and treatment candidates
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive intelligence, providing clear and near ...
-
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October. Event: Cantor Neurology ...
By Lumos Pharma
-
Biosceptre Wins Funding from the UK Government-Backed, SMART Award to Develop Novel Cancer Diagnostic and Therapeutic Targets
Cambridge, UK, 8th February 2016 – Biosceptre, a biopharmaceutical company developing innovative diagnostic and therapeutic approaches to cancer, today announced that the UK government-backed Innovate UK SMART award scheme, has awarded the company £100,000 to support pre-clinical development of diagnostic approaches and antibodies to target Kidney and Lung cancers. This project will ...
-
Lumos Pharma Announces Share Repurchase Program
Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), today announced that its board of directors has authorized a share repurchase program to acquire up to $3 million of the Company’s common stock. The Company may purchase ...
By Lumos Pharma
-
Sirenas Receives Research Grant Totaling $1.68 M To Accelerate Its Drug Discovery Technology, ATLANTIS™
Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from nature's chemistry, announced that it has received a new grant from the Bill & Melinda Gates Foundation to advance ATLANTIS™, the company's proprietary drug discovery technology. With today's announcement, Sirenas has now received two research grant awards from ...
By Sirenas
-
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today shared enhanced antigen presenting cell (eAPC) preclinical data demonstrating that delivery of multiple mRNAs encoding for disease-specic antigens together with immune stimulators (CD86 costimulatory factor and membrane bound IL-2 and ...
-
SQZ Biotechnologies Announces Integrated Point-ofCare Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ) announced today that the company’s rst generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specications relative to current clean room-based processes used in clinical development. The non-clinical studies showed that the ...
-
ImmunogenX and Mayo Clinic CeliacShield Trial for Latiglutenase Passes Safety and Efficacy Midterm Assessment
The Data and Safety Monitoring Board (DSMB) for the CeliacShield Trial (NCT03585478) convened June 17, 2020 and immediately approved the continuation of the trial for Latiglutenase, a therapeutic candidate for celiac disease (CD), being conducted at the Mayo Clinic (Rochester, MN). This midpoint futility analysis reviewed the primary histologic endpoint of villous height to crypt depth ratio ...
-
Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001
Stratford-upon-Avon, UK: April, 6 2020 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, announces an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001. The first patient was successfully dosed in the Company’s Heartcel clinical trial of its novel iMP cells in patients with cardiomyopathy on March 16, 2020 ...
By Celixir plc
-
Biosceptre publishes a clinical study of topical drug BIL010t as therapy for BCC
Biosceptre has published a clinical study demonstrating that its topical drug BIL010t provides a novel, safe and tolerable topical therapy for BCC in the British Journal of Dermatology (BJD). Basal cell carcinoma (BCC) is the most common type of cancer, and its incidence is increasing. Biosceptre has discovered a variant of an important signalling protein P2X7, termed nfP2X7, that occurs in the ...
-
Galera to Present at Jefferies Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at ...
-
DermBiont Announces Positive Results in Phase 2a Clinical Trial in Atopic Dermatitis with a Topical Live Biotherapeutic
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, - announced today that its Phase 2a clinical trial with its investigational drug product, DBI-001, in atopic dermatitis, has demonstrated decreases in the abundance in S. aureus, improvement in signs and symptoms of atopic dermatitis, and no safety or ...
-
Galera to Present at H.C. Wainwright BioConnect Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January ...
-
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen ...
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: ...
By Lumos Pharma
-
< Back to Home Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors
Actym Therapeutics, a biotechnology company focused on the discovery and development of novel therapies intended to transform the treatment of cancer, and Wacker Biotech announced today that they have signed a contract for the manufacturing of Actym's lead clinical candidate, ACTM-838, for the treatment of solid tumors. Under the terms of the agreement, Wacker Biotech will initiate GMP (Good ...
-
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a next-generation gene therapy company, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you